American Century Companies Inc. Sells 18,213 Shares of Vaxcyte, Inc. $PCVX

Key Points

• American Century Companies Inc. reduced its holdings in Vaxcyte, Inc. by 3.0%, now owning 587,054 shares valued at approximately $22.17 million.
• Despite a recent earnings miss, analysts maintain a consensus "Buy" rating for Vaxcyte, with a target price of $136.50.
• Vaxcyte currently has a market capitalization of $4.19 billion and reported a P/E ratio of -7.86.

American Century Companies Inc. cut its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 587,054 shares of the company's stock after selling 18,213 shares during the period. American Century Companies Inc. owned about 0.46% of Vaxcyte worth $22,167,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its position in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after acquiring an additional 1,071 shares in the last quarter. IFP Advisors Inc grew its position in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after acquiring an additional 1,306 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Vaxcyte in the fourth quarter worth approximately $214,000. Nisa Investment Advisors LLC grew its position in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after acquiring an additional 293 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Vaxcyte in the fourth quarter worth approximately $248,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Cowen reissued a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Performance

Shares of PCVX stock traded up $0.02 during mid-day trading on Friday, reaching $30.79. The company's stock had a trading volume of 944,896 shares, compared to its average volume of 1,519,997. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The company has a market cap of $4.00 billion, a P/E ratio of -7.49 and a beta of 1.21. The firm's 50-day moving average is $33.34 and its two-hundred day moving average is $42.76.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period last year, the business posted ($1.10) EPS. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.